This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Ariad Pharma Plunges On Disclosure Of Iclusig Toxicity

CAMBRIDGE, Mass. (TheStreet) -- Ariad Pharmaceuticals' (ARIA) admitted Wednesday that its leukemia drug Iclusig causes more blood clots and heart-related side effects than previously reported, forcing the company to halt enrollment in Iclusig clinical trials and advise patients currently on the drug to lower the dose.

Shares of Ariad plunged 67.2% to $5.62 in early Wednesday trading.

Going into Wednesday's announcement, Ariad's $4 billion market valuation hinged on the company's ability to grow Iclusig into a front-line therapy for chronic myeloid leukemia (CML). Some investors were shorting Ariad on the belief that Iclusig was too toxic to ever become a blockbuster cancer drug.

Wednesday, the shorts were proven right about Iclusig's safety risks. Ariad bulls who insisted Iclusig's safety was not a problem made the wrong call.

After examining two years of follow-up data from the clinical study used for Iclusig's approval, Ariad discovered the rate of serious arterial blood clots had risen to almost 12%. This compares to a blood clot rate of 8% after one year of follow up in Iclusig-treated patients.

The higher incidence of arterial blood clots caused by Iclusig led to heart-related safety events in 6.2% of patients and strokes in 4% of patients, Ariad said.

After discussions with the FDA, Ariad has halted enrollment in all ongoing Iclusig clinical trials, including the so-called EPIC study which compares Iclusig to Novartis' (NVS) Gleevec in front-line CML patients. The EPIC study is the linchpin of Ariad's strategy to boost sales of Iclusig by moving into the larger pool of newly diagnosed CML patients.

Ariad had also instructed doctors treated CML patients currently with Iclusig to lower the prescribed dose.

The FDA will be issuing its own safety warning to doctors about Iclusig, Ariad said. Further changes to Iclusig's label are also likely.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs